Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks - 2Wizz CEO: We’re going to invest $1 b. in Israeli market
- 3Monetary Security: Building Serious areas of strength for an Establishment
- 46 Arranging Administrations to Change Your Open air Space
- 5The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- Home Wellness Basics: Building Your Home Exercise center
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- Spain and Catholic Church agree to compensate sex abuse victims
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- 5 Cell phones of the Year
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- These 45 exoplanets may be the best places to search for alien life
- King Charles III says he is reducing cancer treatment schedule in 2026
